Comparison of One-Year Outcome of Intravitreal Aflibercept with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Baseline Characteristics
3.2. Visual Acuity
3.3. Visual Gain or Visual Loss
3.4. Central Retinal Thickness
3.5. Polyp Regression Rate
3.6. Retreatment
3.7. Associated Factors
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Wong, R.L.; Lai, T.Y. Polypoidal choroidal vasculopathy: An update on therapeutic approaches. J. Ophthalmic. Vis. Res. 2013, 8, 359–371. [Google Scholar] [PubMed]
- Laude, A.; Cackett, P.D.; Vithana, E.N.; Yeo, I.Y.; Wong, D.; Koh, A.H.; Wong, T.Y.; Aung, T. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease? Prog. Retin. Eye Res. 2010, 29, 19–29. [Google Scholar] [CrossRef] [PubMed]
- Cheung, C.M.G.; Lai, T.Y.Y.; Ruamviboonsuk, P.; Chen, S.J.; Chen, Y.; Freund, K.B.; Gomi, F.; Koh, A.H.; Lee, W.K.; Wong, T.Y. Polypoidal choroidal vasculopathy: Definition, pathogenesis, diagnosis, and management. Ophthalmology 2018, 125, 708–724. [Google Scholar] [CrossRef] [PubMed]
- Sho, K.; Takahashi, K.; Yamada, H.; Wada, M.; Nagai, Y.; Otsuji, T.; Nishikawa, M.; Mitsuma, Y.; Yamazaki, Y.; Matsumura, M.; et al. Polypoidal choroidal vasculopathy: Incidence, demographic features, and clinical characteristics. Arch. Ophthalmol. 2003, 121, 1392–1396. [Google Scholar] [CrossRef] [PubMed]
- Hayashi, H.; Yamashiro, K.; Gotoh, N.; Nakanishi, H.; Nakata, I.; Tsujikawa, A.; Otani, A.; Saito, M.; Iida, T.; Matsuo, K.; et al. Cfh and arms2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. Investig. Ophthalmol. Vis. Sci. 2010, 51, 5914–5919. [Google Scholar] [CrossRef] [PubMed]
- Maruko, I.; Iida, T.; Saito, M.; Nagayama, D.; Saito, K. Clinical characteristics of exudative age-related macular degeneration in japanese patients. Am. J. Ophthalmol. 2007, 144, 15–22. [Google Scholar] [CrossRef] [PubMed]
- Ciardella, A.P.; Donsoff, I.M.; Huang, S.J.; Costa, D.L.; Yannuzzi, L.A. Polypoidal choroidal vasculopathy. Surv. Ophthalmol. 2004, 49, 25–37. [Google Scholar] [CrossRef] [PubMed]
- Bessho, H.; Honda, S.; Imai, H.; Negi, A. Natural course and funduscopic findings of polypoidal choroidal vasculopathy in a japanese population over 1 year of follow-up. Retina 2011, 31, 1598–1602. [Google Scholar] [CrossRef] [PubMed]
- Uyama, M.; Wada, M.; Nagai, Y.; Matsubara, T.; Matsunaga, H.; Fukushima, I.; Takahashi, K.; Matsumura, M. Polypoidal choroidal vasculopathy: Natural history. Am. J. Ophthalmol. 2002, 133, 639–648. [Google Scholar] [CrossRef]
- Koh, A.; Lee, W.K.; Chen, L.J.; Chen, S.J.; Hashad, Y.; Kim, H.; Lai, T.Y.; Pilz, S.; Ruamviboonsuk, P.; Tokaji, E.; et al. Everest study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012, 32, 1453–1464. [Google Scholar] [CrossRef]
- Lim, T.H.; Lai, T.Y.Y.; Takahashi, K.; Wong, T.Y.; Chen, L.J.; Ruamviboonsuk, P.; Tan, C.S.; Lee, W.K.; Cheung, C.M.G.; Ngah, N.F.; et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The everest ii randomized clinical trial. JAMA Ophthalmol. 2020, 138, 935–942. [Google Scholar] [CrossRef]
- Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S.D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; et al. Vegf-trap: A vegf blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 2002, 99, 11393–11398. [Google Scholar] [CrossRef]
- Cho, H.J.; Kim, K.M.; Kim, H.S.; Han, J.I.; Kim, C.G.; Lee, T.G.; Kim, J.W. Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 2016, 165, 1–6. [Google Scholar] [CrossRef]
- Matsumiya, W.; Honda, S.; Otsuka, K.; Miki, A.; Nagai, T.; Imai, H.; Kusuhara, S.; Nakamura, M. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Graefe’s Arch. Clin. Exp. Ophthalmol./Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 2017, 255, 541–548. [Google Scholar] [CrossRef] [PubMed]
- Treatment of age-related macular degeneration with photodynamic therapy (tap) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials–tap report. Arch. Ophthalmol. 1999, 117, 1329–1345. [Google Scholar] [CrossRef]
- Participants, V.R. Guidelines for using verteporfin (visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: Update. Retina 2005, 25, 119–134. [Google Scholar] [CrossRef]
- Takayama, K.; Kaneko, H.; Kataoka, K.; Hattori, K.; Ra, E.; Tsunekawa, T.; Fukukita, H.; Haga, F.; Ito, Y.; Terasaki, H. Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study. PLoS ONE 2017, 12, e0176100. [Google Scholar] [CrossRef] [PubMed]
- Kikushima, W.; Sakurada, Y.; Sugiyama, A.; Tanabe, N.; Kume, A.; Iijima, H. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy. Graefe’s Arch. Clin. Exp. Ophthalmol./Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 2017, 255, 311–316. [Google Scholar]
- Silva, R.; Arias, L.; Nunes, S.; Farinha, C.; Coimbra, R.; Marques, J.P.; Cachulo, M.L.; Figueira, J.; Barreto, P.; Madeira, M.H.; et al. Efficacy and safety of intravitreal aflibercept treat and extend for polypoidal choroidal vasculopathy in the atlantic study: A randomized clinical trial. Ophthalmologica. Journal international d’ophtalmologie. Int. J. Ophthalmol./Z. Fur Augenheilkd. 2022, 245, 80–90. [Google Scholar]
- Brown, D.M.; Kaiser, P.K.; Michels, M.; Soubrane, G.; Heier, J.S.; Kim, R.Y.; Sy, J.P.; Schneider, S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355, 1432–1444. [Google Scholar] [CrossRef]
- Kang, H.M.; Koh, H.J.; Lee, C.S.; Lee, S.C. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: Long-term visual outcome. Am. J. Ophthalmol. 2014, 157, 598–606.e591. [Google Scholar] [CrossRef] [PubMed]
- Oishi, A.; Kojima, H.; Mandai, M.; Honda, S.; Matsuoka, T.; Oh, H.; Kita, M.; Nagai, T.; Fujihara, M.; Bessho, N.; et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month laptop study results. Am. J. Ophthalmol. 2013, 156, 644–651. [Google Scholar] [CrossRef]
- Oishi, A.; Miyamoto, N.; Mandai, M.; Honda, S.; Matsuoka, T.; Oh, H.; Kita, M.; Nagai, T.; Bessho, N.; Uenishi, M.; et al. Laptop study: A 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy. Ophthalmology 2014, 121, 1151–1152. [Google Scholar] [CrossRef] [PubMed]
- Ogura, Y.; Iida, T.; Lee, W.K.; Cheung, C.M.G.; Mitchell, P.; Leal, S.; Schmelter, T.; Ishibashi, T. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 96-week outcomes in the japanese subgroup of the planet study. Jpn. J. Ophthalmol. 2021, 65, 344–353. [Google Scholar] [CrossRef] [PubMed]
- Liu, S.; Chhabra, R. Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a european cohort. Graefe’s Arch. Clin. Exp. Ophthalmol./Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 2022, 260, 3533–3542. [Google Scholar] [CrossRef] [PubMed]
- Wataru, K.; Sugiyama, A.; Yoneyama, S.; Matsubara, M.; Fukuda, Y.; Parikh, R.; Sakurada, Y. Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. PLoS ONE 2020, 15, e0229231. [Google Scholar] [CrossRef]
- Lee, J.; Kim, K.; Kim, E.S.; Yu, S.Y.; Kang, M.S. Seven-year outcomes of combined treatment of anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy; according to polypoidal lesion regression. BMC Ophthalmol. 2023, 23, 511. [Google Scholar] [CrossRef]
IVA (n = 30) | IVA/PDT (n = 30) | p-Value | |
---|---|---|---|
Age (year) | 65.0 ± 14.8 | 65.5 ± 12.8 | 0.896 |
Sex (male %) | 53.3% | 76.7% | 0.052 |
Lens status (phakic %) | 70.0% | 66.7% | 0.500 |
Baseline BCVA (LogMAR) | 0.63 ± 0.48 | 0.73 ± 0.65 | 0.499 |
Baseline CRT (μm) | 316 ± 129 | 339 ± 96 | 0.443 |
IVA (n = 30) | IVA/PDT (n = 30) | p-Value | |
---|---|---|---|
Changes in BCVA from baseline to 12-month (LogMAR) | 0.05 ± 0.48 | 0.22 ± 0.44 | 0.146 |
BCVA gain ≧ 0.3 LogMAR at 12-month | 30.0% | 33.3% | 0.500 |
BCVA loss ≧ 0.3 LogMAR at 12-month | 20.0% | 6.7% | 0.127 |
Changes in CRT from baseline to 12-month (μm) | 69 ± 141 | 83 ± 98 | 0.642 |
3-month complete polyp regression rate | 50.0% | 53.3% | 0.500 |
12-month dry macular rate | 60.0% | 96.7% | 0.001 * |
IVA (n = 30) | IVA/PDT (n = 30) | p-Value | |
---|---|---|---|
Retreatment times | |||
1 | 4 | 6 | |
2 | 6 | 0 | |
3 | 6 | 0 | |
4 | 1 | 0 | |
Total (%) | 17 (56.7%) | 6 (20%) | 0.004 * |
Mean retreatment times | 1.27 ± 1.31 | 0.20 ± 0.41 | <0.001 * |
Retreatment modality | |||
IVA only | 17 | 0 | |
IVA/PDT combination | 0 | 6 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Weng, H.-Y.; Chen, F.-T.; Wang, L.-U.; Huang, T.-L.; Ho, W.-T.; Chang, P.-Y.; Hsu, Y.-R.; Chen, Y.-J.; Wang, J.-K. Comparison of One-Year Outcome of Intravitreal Aflibercept with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Medicina 2024, 60, 1311. https://doi.org/10.3390/medicina60081311
Weng H-Y, Chen F-T, Wang L-U, Huang T-L, Ho W-T, Chang P-Y, Hsu Y-R, Chen Y-J, Wang J-K. Comparison of One-Year Outcome of Intravitreal Aflibercept with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Medicina. 2024; 60(8):1311. https://doi.org/10.3390/medicina60081311
Chicago/Turabian StyleWeng, Hsin-Yu, Fang-Ting Chen, Ling-Uei Wang, Tzu-Lun Huang, Wei-Ting Ho, Pei-Yao Chang, Yung-Ray Hsu, Yun-Ju Chen, and Jia-Kang Wang. 2024. "Comparison of One-Year Outcome of Intravitreal Aflibercept with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy" Medicina 60, no. 8: 1311. https://doi.org/10.3390/medicina60081311